Total Payments
$180,846
2024 Payments
$34,021
Companies
11
Transactions
152
Medicare Patients
610
Medicare Billing
$125,643
Payment Breakdown by Category
Other$123,908 (68.5%)
Travel$33,511 (18.5%)
Consulting$20,463 (11.3%)
Food & Beverage$2,103 (1.2%)
Research$750.00 (0.4%)
Education$110.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $123,908 | 34 | 68.5% |
| Travel and Lodging | $33,511 | 76 | 18.5% |
| Consulting Fee | $20,463 | 6 | 11.3% |
| Food and Beverage | $2,103 | 31 | 1.2% |
| Unspecified | $750.00 | 2 | 0.4% |
| Education | $110.62 | 3 | 0.1% |
Payments by Type
General
$180,096
150 transactions
Research
$750.00
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $105,738 | 82 | $0 (2024) |
| Gilead Sciences, Inc. | $39,417 | 30 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $11,106 | 12 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $9,499 | 6 | $0 (2022) |
| PFIZER INC. | $6,668 | 6 | $0 (2023) |
| Puma Biotechnology, Inc. | $4,024 | 9 | $0 (2018) |
| Stemline Therapeutics Inc. | $2,160 | 1 | $0 (2023) |
| Daiichi Sankyo Inc. | $1,370 | 1 | $0 (2020) |
| Eli Lilly and Company | $750.00 | 2 | $0 (2023) |
| Seattle Genetics, Inc. | $98.70 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,021 | 27 | Merck Sharp & Dohme LLC ($17,593) |
| 2023 | $86,231 | 58 | Merck Sharp & Dohme LLC ($64,686) |
| 2022 | $31,695 | 31 | Merck Sharp & Dohme LLC ($23,373) |
| 2021 | $4,280 | 4 | AstraZeneca Pharmaceuticals LP ($4,268) |
| 2020 | $4,820 | 2 | AstraZeneca Pharmaceuticals LP ($3,450) |
| 2019 | $14,673 | 16 | Novartis Pharmaceuticals Corporation ($10,117) |
| 2018 | $5,112 | 13 | Puma Biotechnology, Inc. ($4,024) |
| 2017 | $13.98 | 1 | EMD Serono, Inc. ($13.98) |
All Payment Transactions
152 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/04/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,950.00 | General |
| Category: ONC | ||||||
| 08/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $1,296.45 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $631.75 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $231.15 | General |
| Category: ONCOLOGY | ||||||
| 08/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $28.04 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,190.00 | General |
| Category: ONC | ||||||
| 04/24/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $634.20 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $41.13 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: ONC | ||||||
| 04/20/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: ONC | ||||||
| 04/19/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $23.76 | General |
| Category: ONC | ||||||
| 04/10/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 04/09/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Travel and Lodging | In-kind items and services | $788.44 | General |
| Category: ONCOLOGY | ||||||
| 04/09/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $62.44 | General |
| Category: ONCOLOGY | ||||||
| 03/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,950.00 | General |
| Category: ONC | ||||||
| 03/07/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: ONC | ||||||
| 01/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+, HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $450.00 | 1 |
| A PHASE 1A/1B STUDY OF LY3484356 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH ABEMACICLIB TO PATIENTS WITH ER+ HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 236 | 470 | $215,292 | $39,227 |
| 2022 | 6 | 195 | 386 | $235,966 | $42,935 |
| 2021 | 4 | 122 | 269 | $146,793 | $32,394 |
| 2020 | 2 | 57 | 129 | $56,533 | $11,087 |
Total Patients
610
Total Services
1,254
Medicare Billing
$125,643
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 90 | 196 | $124,068 | $22,202 | 17.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 28 | 51 | $21,981 | $4,083 | 18.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 64 | 156 | $22,464 | $4,023 | 17.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $20,286 | $3,420 | 16.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 19 | 19 | $15,143 | $2,948 | 19.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 25 | $11,350 | $2,551 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 86 | 220 | $139,260 | $25,533 | 18.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 28 | $24,696 | $4,704 | 19.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 44 | $19,976 | $3,837 | 19.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 24 | 46 | $19,826 | $3,492 | 17.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 21 | 21 | $16,737 | $3,283 | 19.6% |
| 99356 | Extended inpatient or observation hospital service, first hour | Facility | 2022 | 17 | 27 | $15,471 | $2,086 | 13.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 65 | 199 | $107,592 | $23,882 | 22.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $15,855 | $3,385 | 21.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 23 | 36 | $11,880 | $2,876 | 24.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $11,466 | $2,251 | 19.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 40 | 106 | $51,414 | $10,106 | 19.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 17 | 23 | $5,119 | $981.17 | 19.2% |
About Dr. Ritesh Parajuli, MD
Dr. Ritesh Parajuli, MD is a Internal Medicine healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1710189543.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ritesh Parajuli, MD has received a total of $180,846 in payments from pharmaceutical and medical device companies, with $34,021 received in 2024. These payments were reported across 152 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($123,908).
As a Medicare-enrolled provider, Parajuli has provided services to 610 Medicare beneficiaries, totaling 1,254 services with total Medicare billing of $125,643. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Orange, CA
- Active Since 06/04/2007
- Last Updated 06/20/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1710189543
Products in Payments
- KEYTRUDA (Biological) $71,591
- Trodelvy (Drug) $39,405
- LYNPARZA (Biological) $34,062
- KISQALI (Drug) $10,333
- TALZENNA (Drug) $4,470
- Nerlynx (Drug) $4,024
- Orserdu (Drug) $2,160
- LYNPARZA (Drug) $1,713
- Enhertu (Drug) $1,370
- Bavencio (Biological) $13.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Orange
Dr. May Cho, M.d, M.D
Internal Medicine — Payments: $335,831
Internal Medicine $335,831
Dr. Elizabeth Brem, Md, MD
Internal Medicine — Payments: $285,872
Internal Medicine $285,872
Beth Valashinas, Do, DO
Internal Medicine — Payments: $96,719
Internal Medicine $96,719
Dr. Jennifer Valerin, M.d, M.D
Internal Medicine — Payments: $83,603
Internal Medicine $83,603
Dr. Teferi Mitiku, M.d, M.D
Internal Medicine — Payments: $69,169
Internal Medicine $69,169
Sendhil Krishnan, Md, Facc, MD, FACC
Internal Medicine — Payments: $40,364
Internal Medicine $40,364